Dr. Tram Tran, the Chief Medical Officer at Glympse Bio, is taking the knowledge about the mechanistic roles protease play in many diseases to develop an injectable biosensor to measure protease activity rather than just a one-time measurement of the amount of protein in the blood. The platform uses machine learning to analyze different protease levels and the protease activity over time to come up with a classifier and differentiate between disease activity and not disease activity.

Tram explains, "So, a couple of years ago, though, I think recognizing that having an injectable platform and then having the patient urinate and check the urine for the level of protease activity might be a little bit more complicated than what would be ideal in the clinic for the patient. We actually were able to switch over to a blood-based test, where we are able to measure the patient's disease activity via protease activity via a simple blood test. And so, I think that was really a remarkable change over the past couple of years."

"We've been working on a couple of different diseases and better understanding how to measure and understand diseases and protease activity through a simple blood test now. So, I think that's really important. This ex vivo platform development was a key change. We presented data last year on NASH, which is a very common disease, non-alcoholic steatohepatitis. And this year, we're talking more about liver cancer or hepatocellular carcinoma."

@GlympseBio #Diagnostic #Biosensor #LiverDisease #HCC #HepatocellularCarcinoma #ProteinActivity #Protease

GlympseBio.com

Download the transcript here

Daily Poll: Should Pete Rose be posthumously admitted to the Baseball Hall Of Fame?